Search the Newsreel

Why (ATRA) Price Action Is Critical for Tactical Trading

This article analyzes Atara Biotherapeutics Inc. (NASDAQ: ATRA) for tactical trading, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies an exceptional 234.0:1 risk-reward setup targeting a 70.2% gain against 0.3% risk. The analysis also provides specific institutional trading …

DA Davidson reiterates Dynatrace stock Buy rating on Arize deal

DA Davidson has reiterated its Buy rating and a $65.00 price target for Dynatrace Inc. (NYSE:DT) following the company's acquisition of Arize for $915 million, a move expected to accelerate Dynatrace's expansion into AI Observability and boost ARR growth. This strategic acquisition, supported by …

Dynatrace Falls as Investors Weigh $915 Million Arize Deal

Dynatrace (DT) shares fell 3.3% after investors reacted to its planned $915 million acquisition of AI observability company Arize. While the deal is intended to boost ARR growth, concerns arose over the significant purchase price, cash-and-stock structure, and management's statement that it would dilute …

Starboard adds Dynatrace, Flowserve, and exits Beckton Dickson, among top Q2 trades

takasuu/iStock via Getty Images Starboard Value added Dynatrace (DT [https://seekingalpha.com/symbol/DT]) and Flowserve (FLS [https://seekingalpha.com/symbol/FLS]), while the fund exited Beckton Dickinson (BDX [https://seekingalpha.com/symbol/BDX]) and Gen Digital (GEN [https://seekingalpha.com/symbol/GEN]), according to its latest 13F filing. The activist fund led by Jeff Smith added 8.9M Dynatrace (DT …

Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake

Point72 entities, including Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, have reported a 7.6% beneficial stake in Atara Biotherapeutics (ATRA). This stake, totaling 687,718 shares of common stock, is held by Point72 Associates, LLC, an investment fund managed by …

Dynatrace (NYSE:DT) Given New $60.00 Price Target at Truist Financial

Truist Financial has increased its price target for Dynatrace (NYSE:DT) to $60.00 from $55.00, maintaining a "buy" rating, which suggests a 20.65% upside. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of $0.48 against an anticipated $0.45, and revenue of $554.55 million, …

Dynatrace's Arize Acquisition Seen to Accelerate Organic Growth, RBC Capital Markets Says

RBC Capital Markets believes that Dynatrace's acquisition of Arize AI, Inc. will accelerate the company's organic growth. Dynatrace has signed a definitive agreement to acquire Arize AI for approximately $920 million in a deal involving cash and stock. This news comes alongside several analyst …

5 Insightful Analyst Questions From Dynatrace’s Q2 Earnings Call

5 Insightful Analyst Questions From Dynatrace's Q2 Earnings Call Dynatrace's second quarter was marked by strong revenue growth and a positive market response, as the company surpassed Wall Street's revenue expectations and posted robust demand for its cloud observability platform. Management attributed this momentum …

Dynatrace Buys US Startup Arize for $915 Million to Strengthen Its Position in the AI Race

Dynatrace has acquired the US startup Arize for $915 million, comprising $815 million in cash and replacement equity awards. This acquisition aims to enhance Dynatrace's AI observability capabilities by integrating Arize's platform, which monitors machine learning models and AI agents in production. The deal …

Yatra Online makes Q1FY27 earnings call audio available

Yatra Online Q4 2025 Earnings Call: Complete Transcript

Dynatrace, Inc. (NYSE:DT) signed a definitive agreement to acquire Arize AI, Inc for approximately $920 million.

Dynatrace, Inc. has entered into a definitive agreement to acquire Arize AI, Inc. for approximately $920 million. The acquisition will involve $815 million in cash and replacement equity awards for Arize employees joining Dynatrace, funded by cash on hand and/or existing credit facilities. The …

DT Looks 27.9% Undervalued on GF Value™

Dynatrace Inc (NYSE: DT) is considered modestly undervalued by 27.9% according to GuruFocus’ GF Value™ metric, trading at $49.56 against an intrinsic value of $68.77. The company's GF Score™ of 87/100 reflects strong financial health, driven by exceptional growth and solid momentum, despite a …

Dynatrace’s $915M Arize deal would link AI evaluation to production

Dynatrace (NYSE: DT) has announced its acquisition of Arize, an AI observability leader, for $915 million in cash and stock. This acquisition aims to create the industry's most comprehensive AI development lifecycle solution, enabling customers to evaluate, operate, and continuously improve AI applications from …

Dynatrace to Acquire AI Observability Leader Arize

Acquisition will provide the industry's most comprehensive AI development lifecycle solution BOSTON & SAN FRANCISCO, August 13, 2026--(BUSINESS WIRE)--Dynatrace (NYSE: DT), the leading AI-powered observability platform, has signed a definitive agreement to acquire Arize in a cash and stock transaction valued at $915 million. …

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics reported its Q2 2026 financial results, highlighting a productive meeting with the FDA for tabelecleucel, which confirmed the opportunity to resubmit its BLA. The company announced significant cost reductions and expects its current cash and investments to fund operations into mid-2027. Net …

Yatra Online consolidated net profit declines 97.88% in the June 2026 quarter

Atara Biotherapeutics Q2 Results: Sales beat estimates, EPS in line

Atara Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of $(0.32), which was in line with analyst estimates. While the company's sales of $630,000 beat the consensus estimate by 71.82%, this figure still represented a significant 96.42% year-over-year decline from $17.575 million, and EPS swung from …

Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates

Atara Biotherapeutics Inc (ATRA) reported second-quarter earnings per share of $-0.3200, missing analyst estimates by $0.10. The company's revenue for the quarter was $630K, falling short of the consensus estimate of $2.55M. The stock has seen a decline of -3.71% over the last three …

Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly earnings that matched analyst expectations for a loss of $0.32 per share, while revenue of $0.63 million surpassed estimates. Despite ongoing negative profitability metrics, the stock rose 3.2% after the announcement. Institutional investors hold a significant portion of the …

Yatra Online net profit falls 98% in Q1FY27 to ₹3.5 Mn on margin pressure

Yatra Online Q1 Results: Net profit falls 98% YoY to ₹3 Mn

Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary

Atara Biotherapeutics reported second-quarter 2026 results with revenue of $0.63 million, a significant drop from the previous year, and a consolidated net loss of $9 million for the six months ending June 30, 2026. The company experienced a sharp decline in commercial revenue due …

Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Expects Cash and Cost Cuts to Fund Operations Into Mid-2027

Atara Biotherapeutics announced its second-quarter 2026 financial results, highlighting productive discussions with the FDA regarding the resubmission of its tabelecleucel BLA. The company reported a net loss of $4.8 million for the quarter but expects its current cash, cash equivalents, and short-term investments, combined …

Dynatrace Recognizes Carahsoft With Rising Star for North America Award for 2026

Carahsoft Technology Corp. RESTON, Va., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Carahsoft Technology Corp., The Trusted Government IT Solutions Provider®, today announced that it has been named the Rising Star for North America by Dynatrace, (NYSE: DT), a leading AI-powered observability platform. The award …

Dynatrace (DT) Q1 2027 Earnings Call Transcript

Dynatrace reported a strong Q1 FY27, exceeding revenue and profitability guidance, with total ARR growing 17% and net new ARR up 66%. The company highlighted increasing demand for its unified observability platform driven by complex cloud-native workloads and AI initiatives, with AI-related consumption growing …

Dynatrace (DT) Could Be 36% Undervalued Following AI Demand And Mixed Guidance

Dynatrace Says AI Workloads Fuel Observability Demand, Consumption Growth

Key Points Interested in Dynatrace, Inc.? Here are five stocks we like better. AI workloads are driving demand for observability as enterprises need end-to-end monitoring of AI performance, accuracy, security and outputs. Dynatrace says AI-related customers consume its platform at roughly 1.5 times the …

Atara Biotherapeutics (ATRA) Earnings Date and Reports 2026 $ATRA

Why Dynatrace (DT) Is Up 9.9% After Mixed Q1, AI Launches, And Buyback Update

Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline?

Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to release a quarterly update today. This update is expected to provide clarity on the company's program focus, funding discipline, the quality of current demand, and its ability to translate operating priorities into sustainable performance. The article emphasizes that …

Yatra Online Inc to report Q1FY27 results on Aug 12